Basilea Pharmaceutica BSLN

SWX: BSLN | ISIN: CH0011432447 3/05/2024

39,90 CHF (+0,76%)

(+0,76%) 3/05/2024

Grafiek Basilea Pharmaceutica

Grafiek Basilea Pharmaceutica

1 dag1d 0,76%
1 week1w -0,75%
1 maand1m -6,56%
3 maanden3m 22,21%
6 maanden6m 10,53%
1 jaar1j -13,26%
5 jaar5j -10,30%

Basilea Pharmaceutica in het nieuws

Toon enkel gratis nieuws

3 mei 2024 · Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024 · Persbericht

24 april 2024 · Basilea shareholders approve all proposals of the board of directors at the annual general meeting · Persbericht

9 april 2024 · Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics · Persbericht

4 april 2024 · Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications · Persbericht

11 maart 2024 · Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

13 februari 2024 · Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio · Persbericht

19 januari 2024 · Cresemba® sales in Latin America trigger first sales milestone payment to Basilea · Persbericht

15 januari 2024 · Basilea announces acquisition of preclinical antibiotics program from Spexis · Persbericht

5 januari 2024 · Basilea provides portfolio status update · Persbericht

20 december 2023 · Basilea announces accelerated loan repayment · Persbericht

Profiel Basilea Pharmaceutica

CEO: Ronald Scott

Aandelen Basilea Pharmaceutica

Beurswaarde: 522,75 miljoen CHF

Effecten: 13,10 miljoen

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe